DarioHealth (NASDAQ:DRIO) Given New $8.00 Price Target at TD Cowen

DarioHealth (NASDAQ:DRIO) had its price objective dropped by stock analysts at TD Cowen from $11.00 to $8.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm presently has a “hold” rating on the stock. TD Cowen’s price target would indicate a potential upside of 3.76% from the stock’s previous close.

Several other research firms have also commented on DRIO. Stifel Nicolaus reiterated a “buy” rating and issued a $10.00 price objective on shares of DarioHealth in a research note on Thursday, May 14th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of DarioHealth in a report on Friday, July 10th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, DarioHealth currently has an average rating of “Hold” and an average price target of $9.00.

DarioHealth Stock Up 0.5%

NASDAQ:DRIO traded up $0.04 during trading hours on Wednesday, hitting $7.71. 7,123 shares of the company traded hands, compared to its average volume of 15,280. The company has a quick ratio of 2.62, a current ratio of 3.07 and a debt-to-equity ratio of 0.50. The company has a market cap of $56.59 million, a PE ratio of -0.87 and a beta of 1.11. The firm’s 50-day simple moving average is $7.10 and its 200-day simple moving average is $8.30. DarioHealth has a one year low of $5.84 and a one year high of $17.74.

DarioHealth (NASDAQ:DRIO) last announced its earnings results on Tuesday, August 11th. The company reported ($0.85) EPS for the quarter, beating the consensus estimate of ($1.22) by $0.37. DarioHealth had a negative net margin of 192.23% and a negative return on equity of 60.52%. The company had revenue of $5.18 million during the quarter, compared to the consensus estimate of $5.92 million. Equities analysts predict that DarioHealth will post -3.12 earnings per share for the current year.

Insider Buying and Selling

In other DarioHealth news, Director Dennis Matheis bought 14,430 shares of the stock in a transaction on Thursday, July 23rd. The shares were acquired at an average price of $6.93 per share, with a total value of $99,999.90. Following the acquisition, the director directly owned 43,026 shares of the company’s stock, valued at $298,170.18. The trade was a 50.46% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 3.50% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in DRIO. BlackRock Inc. purchased a new position in DarioHealth during the 2nd quarter valued at about $249,000. Kestra Advisory Services LLC purchased a new position in DarioHealth during the fourth quarter valued at approximately $35,000. Geode Capital Management LLC increased its holdings in DarioHealth by 167.9% during the 4th quarter. Geode Capital Management LLC now owns 49,567 shares of the company’s stock worth $564,000 after acquiring an additional 31,063 shares during the period. Finally, XTX Topco Ltd increased its holdings in DarioHealth by 229.0% during the 2nd quarter. XTX Topco Ltd now owns 62,511 shares of the company’s stock worth $42,000 after acquiring an additional 43,513 shares during the period. Institutional investors own 33.39% of the company’s stock.

Key DarioHealth News

Here are the key news stories impacting DarioHealth this week:

• Positive Sentiment: Revenue totaled approximately $5.2 million, while the quarterly loss per share was narrower than analysts expected. The company also reduced its operating loss by 30% year over year and operating expenses by 21%, indicating improving cost discipline. DarioHealth Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Gross margin improved to 62% from 57% in the prior quarter and 55% a year earlier. Dario said its B2B2C gross margin remained approximately 80% for the 10th consecutive quarter, supporting the profitability potential of its business model. DarioHealth Q2 2026 Earnings Highlights
• Positive Sentiment: Management highlighted more than $13.1 million of contracted and late-stage annual recurring revenue, with over 80% tied to its multi-condition platform. Recent wins include an expansion with a top-five national health plan, a Fortune 50 customer and a new health insurer through Amwell; the largest expansion could nearly triple Dario’s potential revenue opportunity with that client. DarioHealth Q2 2026 Earnings Call Transcript
• Positive Sentiment: Dario reported pro forma cash of $36.8 million after raising $22.8 million in July, providing additional funding for product development and commercial expansion.
• Neutral Sentiment: The company expanded into provider-backed clinical care delivery, which could increase revenue per customer but also broadens its execution requirements. A comparison article with Ascom provides industry perspective but does not identify a specific new catalyst for DRIO. Critical Survey: DarioHealth versus Ascom
• Negative Sentiment: Quarterly revenue came in below the roughly $5.9 million consensus estimate, and Dario remains deeply unprofitable. The company’s decision to discontinue certain pharmaceutical-related business also reduced reported revenue, creating a near-term headwind despite the stated focus on higher-quality growth. DarioHealth Reports Q2 Loss and Lags Revenue Estimates
• Negative Sentiment: The July equity financing strengthened liquidity but may dilute existing shareholders. Trading was also temporarily halted under a volatility-based LULD pause, signaling elevated short-term trading risk.

DarioHealth Company Profile

DarioHealth (NASDAQ:DRIO) is a digital health company specializing in chronic disease management through a smartphone-based care platform. Its core solution combines connected devices—such as glucose meters, blood pressure monitors and smart scales—with real-time data analytics and personalized coaching. The platform is designed to support individuals living with diabetes, hypertension, weight management challenges and other cardiometabolic conditions, offering continuous monitoring, tailored insights and behavioral nudges aimed at improving clinical outcomes.

The Dario platform integrates artificial intelligence and machine learning to deliver personalized guidance and education.